ABSTRACT
The high prevalence of myopia is a global public health concern, and the risk of associated complications is becoming increasingly apprent.The International Myopia Institute (IMI) was established in 2015 to promote scientific research and clinical practice in myopia control, and IMI published the White Paper on Myopia Prevention and Control on the diagnosis, treatment, and management of myopia.In 2023, the IMI released the series three of the White Paper on Myopia Prevention and Control, which delves deeper into key issues in myopia research and management.The white paper focuses on non-pathological changes observed in axial myopia, and the role of the choroid in eye growth and myopia management.It also reviews the evidence for myopia incidence, progression and management in atypical populations, such as infants, pre-school children, and young adults.It provides recommendations and strategies for clinical practice in myopia management and summarizes important new findings in myopia research since 2019, which are summarized into the IMI 2023 Digest.This article aims to interpret the key contents of the series three of the White Paper on Myopia Prevention and Control, to help professionals involved in myopia control to stay informed about the latest evidence from international research, to optimize strategies for preventing and treating myopia-related diseases, and ultimately to promote the development of myopia research and management in China.
ABSTRACT
Worldwide, the incidence rate of myopia is maintained in a high level. Especially, the morbidity is rising continuously among children and adolescents. The progression of myopia affects visual acuity, vision related quality of life and productivity. Moreover, high myopia and its related ocular complications also aggravate the family and social burden. Therefore, the mechanism of myopia, related complications and methods of myopia prevention and control need further exploration. International Myopia Institute(IMI)published the second-edition white papers in April 2021. These white papers included reflections on the implications for clinical practice, the impact of myopia, the risk factors of myopia, the relationship among accommodation and binocular vision with myopia, pathologic myopia, prevention of myopia and digest. Comparing to the first edition, more than thousands of articles and conference abstracts were considered in white papers II, highlighting the latest research and progress related to myopia prevention and control. This article briefly summarizes and interprets the contents of the above white papers, including overview of myopia, impact of myopia, risk factors in myopia, ocular changes in the progress of myopia, and myopia prevention and control, hoping to provide advice for the clinical and scientific research work relating to myopia prevention and control.